<DOC>
	<DOCNO>NCT00165659</DOCNO>
	<brief_summary>To evaluate dose-response efficacy E2020 ( 5 mg/day 10 mg/day ) versus placebo verify superiority E2020 placebo patient severe AD use CIBIC-plus* SIB** primary efficacy measure . Safety E2020 also evaluate . ( *for overall evalution clinical symtoms ) ( **for cognitive function test )</brief_summary>
	<brief_title>A Multi-Center , Randomized , Double-Blind , Parallel Group Study With 3 Groups Receiving Placebo , 5 mg E2020 10 mg E2020</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Patients diagnostics Alzheimer 's disease ( AD ) accord DSMIV . Patients modify Hachinski Ischemic scale score ≦6 . FAST score ≧6 baseline ( 4 week start study treatment ) . MMSE score 1 12 baseline ( 4 week start study treatment ) . Imaging diagnostics ( CT , MRI , etc. , within 24 month consistent diagnosis AD without comorbid pathology find . If significant change clinical status suggest type dementia ( except AD ) suspect final image diagnosis time start observation , scan test repeat . Patients comply requirement concomitant drugs/therapies baseline phase . Patients age 50 year old . Outpatients . Even case outpatient patient attend outpatientvisit basis nursing home facility , caregiver must constant reliable informant minimum 3 day per week direct contact patient ( least 4 hour per day waking hour ) . This contact necessary ensure accurate reporting patient 's behavior his/her ability perform ADLs . Patients expect complete procedure schedule Screening Baseline visit reliable caregiver family member agree accompany patient clinic visit , provide information patient require protocol , ensure compliance treatment schedule . Patients swallow tablet without pulverization . Patients ambulatory least aided ( walker ) vision hear necessary compliance test procedure ( eyeglass and/or hear aid permissible ) . Patients whose representative sign write informed consent . Patients dementia AD . 1 . Patient whose image test show `` circumscribed cerebral lesion multiple infarct '' suspect responsible cause dementia ( mixedtype dementia ) 2 . Patients types dementia Patients current DSMIV diagnosis major depressive disorder current serious psychiatric diagnosis othe AD . Patients without reliable caregiver . Patients expect enter nursing home facility within 6 month start study treatment ( exclude transient entry ) . Patients active clinically significant condition affect absorption , distribution metabolism study drug ( e.g. , inflammatory bowel disease , gastric duodenal ulcer , severe lactose intolerance ) . Patients know hypersensitivity component donepezil hydrochloride preparation piperidine derivative . Patients complicate severe gastrointestinal , hepatic , renal , endocrine , cardiovascular system disease ( e.g. , sick sinus syndrome , intraarterial supraventricular conduction disorder , etc. ) . Patients history severe bronchial asthma obstructive pulmonary disease . Patients severe extrapyramidal disease ( Parkinson 's disease , Parkinson 's syndrome , etc. ) . Patients diabetes mellitus uncontrolled blood glucose level ( HbAlc ≧10 % ) . Hypertension patient uncontrolled blood pressure ( diastolic blood pressure ≧95 mmHg ) . Patients uncontrolled thyroid dysfunction . Patients history seizure convulsion within previous 3 month ( obtain inform consent ) . Patients know suspected history alcohoism drug dependence within recent 10 year . Patients malignant tumor . Women pregnant , possibly pregnant , lactate . Patients participate another clinical study within recent 3 month ( give consent ) . Any patient judge ineligible study entry investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>